Skip to main content

Table 3 Relationship between Cx43 expression and clinicopathological factors in patients with HBV-HCC and low AFP levels

From: Connexin-43 can delay early recurrence and metastasis in patients with hepatitis B-related hepatocellular carcinoma and low serum alpha-fetoprotein after radical hepatectomy

  Cx43 χ2 PValue
   - (%) + (%)   
Gender Male 68(42.3%) 71(44.6%) 1.809 0.179
Female 13(8.2%) 7(4.4%)
Age > 60y 18(11.3%) 27(17.0%) 3.008 0.083
≤ 60y 63(39.6%) 51(32.1%)
Edmondson-Steiner classification I–II 51(32.1%) 66(41.5%) 9.969 0.002*
III–IV 30(18.9%) 12(7.5%)
Foci Single 64(40.3%) 72(45.3%) 5.68 0.017*
Multiple 17(10.7%) 6(3.7%)
Tumor size > 5cm 41(25.8%) 48(30.1%) 1.923 0.166
≤ 5cm 40(25.2%) 30(18.9%)
Liver capsule invasion No 24(15.1%) 32(20.1%) 2.262 0.133
Yes 57(35.8%) 46(28.9%)
Satellite foci No 73(45.9%) 73(45.9%) 0.636 0.425
Yes 8(5.0%) 5(3.2%)
Cirrhosis No 4(2.5%) 10(6.3%) 3.075 0.080
Yes 77(48.4%) 68(42.8%)
Vascular tumor thrombosis No 75(47.1%) 78(49.1%) 8.243 0.029*
Yes 6(3.8%) 0(0%)
Microvascular invasion No 21(27.3%) 30(40%) 5.422 0.020
Yes 18(23.4%) 8(10.3%)
Child-Pugh class A 78(49.1%) 78(49.1%) 4.102 0.246
B 3(1.8%) 0(0%)
TNM Stage I–II 79(49.7%) 78(49.1%) 1.857 0.405
III–IV 22(13.8%) 12(7.6%)
1-year recurrence No 50(31.4%) 66(41.5%) 7.544 0.006*
  Yes 31(19.5%) 12(7.6%)   
  1. *P < 0.05. The HBV-HCC database of microvascular invasion was from 1 January 2008 to 31 December 2008; 87 patients entered the statistical analysis.